Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285984695> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W4285984695 endingPage "S12" @default.
- W4285984695 startingPage "S12" @default.
- W4285984695 abstract "Dermatomyositis is an autoimmune skin disease with limited treatment options, and lenabasum is a cannabinoid type 2 receptor agonist with anti-inflammatory properties. Our previous work showed that IFNg and IL31 are increased in DM skin vs. skin from healthy controls and lenabasum reduces type 1 interferon (IFN-1) and IL-31 production by DM PBMCs in vitro. Lenabasum 20 mg BID treatment improved CDASI activity (CDASI-A) scores vs. placebo at 1 year in an international, double-blind, randomized Phase 3 trial. Imaging mass cytometry was done on 66 total FFPE skin biopsies obtained at Baseline and Week 16 in that trial, testing expression of 12 intracellular biomarkers in 9 cell types and using a zero-based, linear mixed effects model and Spearman’s correlation for statistical analyses. Subjects in both treatment groups had similar immune infiltrates in skin at Baseline except plasmacytoid dendritic cells were increased in placebo group (p<0.05). At Week 16, subjects treated with lenabasum 20 mg BID vs. placebo had a significant decrease in IFNg (p<0.05) and phosphorylated-IRF3 (activated transcription factor for IFN-1) (p<0.05) expression. There was a trend towards decrease in IL-31 expression with lenabasum treatment (p=0.08). Absolute change in CDASI-A scores was positively correlated with a change in IL-31 staining (R=0.636, p=0.026). These results suggest clinical benefit of lenabasum on skin disease in DM may be mediated in part through reduction of IFNg and pIRF3 (IFN-1 Type 1) expression." @default.
- W4285984695 created "2022-07-20" @default.
- W4285984695 creator A5010705880 @default.
- W4285984695 creator A5015529313 @default.
- W4285984695 creator A5039511677 @default.
- W4285984695 creator A5044937367 @default.
- W4285984695 creator A5054472615 @default.
- W4285984695 creator A5061091710 @default.
- W4285984695 creator A5074465838 @default.
- W4285984695 creator A5076433609 @default.
- W4285984695 creator A5079567707 @default.
- W4285984695 creator A5086864979 @default.
- W4285984695 creator A5088050812 @default.
- W4285984695 date "2022-08-01" @default.
- W4285984695 modified "2023-10-14" @default.
- W4285984695 title "068 Lenabasum reduces IFNγ and pIRF3 in dermatomyositis skin: Biomarker results from a double-blind phase 3 international randomized controlled trial" @default.
- W4285984695 doi "https://doi.org/10.1016/j.jid.2022.05.122" @default.
- W4285984695 hasPublicationYear "2022" @default.
- W4285984695 type Work @default.
- W4285984695 citedByCount "0" @default.
- W4285984695 crossrefType "journal-article" @default.
- W4285984695 hasAuthorship W4285984695A5010705880 @default.
- W4285984695 hasAuthorship W4285984695A5015529313 @default.
- W4285984695 hasAuthorship W4285984695A5039511677 @default.
- W4285984695 hasAuthorship W4285984695A5044937367 @default.
- W4285984695 hasAuthorship W4285984695A5054472615 @default.
- W4285984695 hasAuthorship W4285984695A5061091710 @default.
- W4285984695 hasAuthorship W4285984695A5074465838 @default.
- W4285984695 hasAuthorship W4285984695A5076433609 @default.
- W4285984695 hasAuthorship W4285984695A5079567707 @default.
- W4285984695 hasAuthorship W4285984695A5086864979 @default.
- W4285984695 hasAuthorship W4285984695A5088050812 @default.
- W4285984695 hasBestOaLocation W42859846951 @default.
- W4285984695 hasConcept C126322002 @default.
- W4285984695 hasConcept C142724271 @default.
- W4285984695 hasConcept C167672396 @default.
- W4285984695 hasConcept C203014093 @default.
- W4285984695 hasConcept C204787440 @default.
- W4285984695 hasConcept C27081682 @default.
- W4285984695 hasConcept C2778751314 @default.
- W4285984695 hasConcept C71924100 @default.
- W4285984695 hasConcept C8891405 @default.
- W4285984695 hasConcept C90924648 @default.
- W4285984695 hasConceptScore W4285984695C126322002 @default.
- W4285984695 hasConceptScore W4285984695C142724271 @default.
- W4285984695 hasConceptScore W4285984695C167672396 @default.
- W4285984695 hasConceptScore W4285984695C203014093 @default.
- W4285984695 hasConceptScore W4285984695C204787440 @default.
- W4285984695 hasConceptScore W4285984695C27081682 @default.
- W4285984695 hasConceptScore W4285984695C2778751314 @default.
- W4285984695 hasConceptScore W4285984695C71924100 @default.
- W4285984695 hasConceptScore W4285984695C8891405 @default.
- W4285984695 hasConceptScore W4285984695C90924648 @default.
- W4285984695 hasIssue "8" @default.
- W4285984695 hasLocation W42859846951 @default.
- W4285984695 hasOpenAccess W4285984695 @default.
- W4285984695 hasPrimaryLocation W42859846951 @default.
- W4285984695 hasRelatedWork W2056385328 @default.
- W4285984695 hasRelatedWork W2220102944 @default.
- W4285984695 hasRelatedWork W2373864009 @default.
- W4285984695 hasRelatedWork W2463801737 @default.
- W4285984695 hasRelatedWork W2577548098 @default.
- W4285984695 hasRelatedWork W3031852375 @default.
- W4285984695 hasRelatedWork W3047967522 @default.
- W4285984695 hasRelatedWork W3112940496 @default.
- W4285984695 hasRelatedWork W4233016836 @default.
- W4285984695 hasRelatedWork W4252207178 @default.
- W4285984695 hasVolume "142" @default.
- W4285984695 isParatext "false" @default.
- W4285984695 isRetracted "false" @default.
- W4285984695 workType "article" @default.